The effects of dosage variation in black seed cumin oil (Nigella sativa L.) use on HbA1c levels and interleukin-17A expression in patients at risks of metabolic syndrome

Agustiarini, Vitri and Darmawan, Endang and Akrom, Akrom (2019) The effects of dosage variation in black seed cumin oil (Nigella sativa L.) use on HbA1c levels and interleukin-17A expression in patients at risks of metabolic syndrome. Pharmaciana, 9 (2). pp. 261-270.

Text 8.Agustiarini_261_270.pdf Download (286kB)

Abstract

Metabolic syndrome causes an imbalance of the immune system and increased levels of HbA1c and IL-17A expression. Black cumin seed oil (BCSO) is known to have antioxidant and immunomodulatory properties. This study reports the effects of dosage variation in BCSO (1.5 and 3 ml per day for 20 days) on HbA1c levels and IL-17A expression in patients at risk of metabolic syndrome at Jetis 1 Public Health Center in Bantul, Yogyakarta. It employed a crossover design in which a total of 66 patients at risk of metabolic syndrome were divided into two groups receiving a sequence of different treatments. Group 1 (N=33) received treatment A first, which was BCSO at a dose of 1.5 ml/day for 20 days. Then, after a washout period of 7 days, it received treatment B, 3 ml of BCSO per day for 20 days. Group 2 followed the same procedure only vice versa, treatment B, then A. The HbA1c levels were measured by the mean plasma glucose (MPG) method, while the IL-17A expression was detected by flow cytometry. The average HbA1c level and IL-17A expression of the treatment groups were statistically analyzed with 95% confidence level. In response to the treatment regime, the HbA1c level of group 1 was 7.34 ± 2.51% (a decrease), and that of group 2 was 7.72 ± 2.44% (an increase). The IL-17 expression in group 1 was 3.74 ± 3.52% (a decrease), and the one in group 2 was 4.07 ± 3.65% (an increase). The effects of administering 1.5 ml and 3 ml BCSO per day for 20 consecutive days on Hb1c level (p=0.17) and IL-17A expression (p=0.67) were not significantly different. Most patients experience a decrease in HbA1c levels and IL-17A expression after the treatment. Insignificant differences between the two groups mean that at the doses of 1.5 ml/day and 3 ml/day for 20 days, BCSO exhibits the same effects in patients at risk of metabolic syndrome registered at Jetis 1 Public Health Center in Bantul, Yogyakarta.

Item Type:	Artikel Umum
Subjects:	R Medicine > RS Pharmacy and materia medica
Divisi / Prodi:	Faculty of Pharmacy (Fakultas Farmasi) > S1-Pharmacy (S1-Farmasi)
Depositing User:	jurnal pharmaciana
Date Deposited:	29 Sep 2021 21:25
Last Modified:	29 Sep 2021 21:25
URI:	http://eprints.uad.ac.id/id/eprint/28779

Actions (login required)

View Item